Answers are grounded in this paper and cite their sources.
Our results suggest the potential for the three-dose schedule of recombinant vaccine Engerix-B 80 microg to prolong the immune response among ESRD population.
No takes yet. Share an insight, caveat, or question.
Chow et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: